Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

The kinematics of cytotoxic lymphocytes influence their ability to kill target cells.

Bhat P, Leggatt G, Matthaei KI, Frazer IH.

PLoS One. 2014 May 6;9(5):e95248. doi: 10.1371/journal.pone.0095248. eCollection 2014.

PMID:
24801876
[PubMed - in process]
Free PMC Article
2.

RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.

Gregerson DS, Lew KL, McPherson SW, Heuss ND, Ferrington DA.

Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5385-94.

PMID:
17122128
[PubMed - indexed for MEDLINE]
Free Article
3.

Differential activation of the death receptor pathway in human target cells induced by cytotoxic T lymphocytes showing different kinetics of killing.

de Vries JF, von dem Borne PA, van Luxemburg-Heijs SA, Heemskerk MH, Willemze R, Falkenburg JH, Barge RM.

Haematologica. 2007 Dec;92(12):1671-8.

PMID:
18055991
[PubMed - indexed for MEDLINE]
Free Article
4.

Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.

Bergmann-Leitner ES, Abrams SI.

Cancer Immunol Immunother. 2001 Nov;50(9):445-55.

PMID:
11761438
[PubMed - indexed for MEDLINE]
5.

Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.

Schirrmacher V, Schild HJ, Gückel B, von Hoegen P.

Immunol Cell Biol. 1993 Aug;71 ( Pt 4):311-26.

PMID:
7901150
[PubMed - indexed for MEDLINE]
Free Article
6.

Murine CD4+ T cell responses are inhibited by cytotoxic T cell-mediated killing of dendritic cells and are restored by antigen transfer.

Ma JZ, Lim SN, Qin JS, Yang J, Enomoto N, Ruedl C, Ronchese F.

PLoS One. 2012;7(5):e37481. doi: 10.1371/journal.pone.0037481. Epub 2012 May 23.

PMID:
22649530
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Derivation of cytotoxic T cell lines that express T cell receptor but exhibit reversible loss of stable antigen binding.

Gnarra JR, Engelhard VH.

J Immunol. 1986 Nov 15;137(10):3057-64.

PMID:
3490508
[PubMed - indexed for MEDLINE]
9.

Visualizing CTL/melanoma cell interactions: multiple hits must be delivered for tumour cell annihilation.

Caramalho I, Faroudi M, Padovan E, Müller S, Valitutti S.

J Cell Mol Med. 2009 Sep;13(9B):3834-46. doi: 10.1111/j.1582-4934.2008.00586.x. Epub 2008 Oct 6.

PMID:
19017355
[PubMed - indexed for MEDLINE]
10.

A three-dimensional organotypic assay to measure target cell killing by cytotoxic T lymphocytes.

Weigelin B, Friedl P.

Biochem Pharmacol. 2010 Dec 15;80(12):2087-91. doi: 10.1016/j.bcp.2010.09.004. Epub 2010 Sep 16.

PMID:
20849829
[PubMed - indexed for MEDLINE]
11.

Heterogeneity of channel catfish CTL with respect to target recognition and cytotoxic mechanisms employed.

Zhou H, Stuge TB, Miller NW, Bengten E, Naftel JP, Bernanke JM, Chinchar VG, Clem LW, Wilson M.

J Immunol. 2001 Aug 1;167(3):1325-32.

PMID:
11466349
[PubMed - indexed for MEDLINE]
Free Article
12.

Antigen presentation and cytotoxic T lymphocyte killing studied in individual, living cells.

Hahn K, DeBiasio R, Tishon A, Lewicki H, Gairin JE, LaRocca G, Taylor DL, Oldstone M.

Virology. 1994 Jun;201(2):330-40.

PMID:
8184542
[PubMed - indexed for MEDLINE]
13.

Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.

Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.

J Immunol. 2002 Apr 1;168(7):3484-92.

PMID:
11907109
[PubMed - indexed for MEDLINE]
Free Article
14.

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

Ferrari G, King K, Rathbun K, Place CA, Packard MV, Bartlett JA, Bolognesi DP, Weinhold KJ.

Clin Exp Immunol. 1995 Aug;101(2):239-48.

PMID:
7544247
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.

Li JH, Rosen D, Sondel P, Berke G.

Immunology. 2002 Mar;105(3):267-77.

PMID:
11918688
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Induction and measurement of cytotoxic T lymphocyte activity.

Wonderlich J, Shearer G, Livingstone A, Brooks A.

Curr Protoc Immunol. 2006 May;Chapter 3:Unit 3.11. doi: 10.1002/0471142735.im0311s72.

PMID:
18432971
[PubMed - indexed for MEDLINE]
17.

Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell.

Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N.

Clin Cancer Res. 2007 Mar 15;13(6):1857-67.

PMID:
17363542
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Cytotoxic T cell lines recognize autologous and allogeneic melanomas with shared or cross-reactive HLA-A.

Hayashi Y, Hoon DS, Park MS, Terasaki PI, Morton DL.

Cancer Immunol Immunother. 1992;34(6):419-23.

PMID:
1373343
[PubMed - indexed for MEDLINE]
20.

Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.

McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK.

Cancer Immunol Immunother. 2000 Oct;49(8):417-25.

PMID:
11043848
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk